Wuxi XDC (02268) plans to use up to 100 million US dollars of internal funds to purchase shares.
Jointown Pharmaceutical Group (02268) announced that the company has decided to use up to 100 million US dollars of internal funds to allow the professional trustees appointed by the company's share plan committee to purchase the company's shares on the open market according to the then-current market price.
WUXI XDC (02268) announced that the company has decided to use up to $100 million of internal funds for the company's appointed professional trustee to buy company shares on the open market at the prevailing market price for its share incentive plan.
The company believes that the current trading price of the shares does not reflect their intrinsic value or the actual business prospects of the company, making it a good opportunity for the proposed share purchase. The board of directors believes that the current financial resources of the group can enable it to implement the proposed share purchase using internal resources, while maintaining a stable financial position for the continued growth of the group's operations.
Related Articles
AIM VACCINE (06660): Wen Jie Resigns as Independent Non-executive Director.
CH BIOTECH SER (08037) intends to sell the entire equity of Standard Pathology Laboratory and Jockey Health for a total of HK$3.5 million
Planned acquisition of 39% equity of Heilongjiang Agriculture Reclamation Agricultural Machinery and Equipment by the First Tractor for a total of 19.7925 million yuan in 1979
AIM VACCINE (06660): Wen Jie Resigns as Independent Non-executive Director.
CH BIOTECH SER (08037) intends to sell the entire equity of Standard Pathology Laboratory and Jockey Health for a total of HK$3.5 million
Planned acquisition of 39% equity of Heilongjiang Agriculture Reclamation Agricultural Machinery and Equipment by the First Tractor for a total of 19.7925 million yuan in 1979
